PBPierFrancesco Bassi

PierFrancesco Bassi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


PierFrancesco Bassi has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Medium-term outcomes after transobturator sling placement for male post-prostatectomy urinary incontinence using a titanised mesh with De Leval technique

    by E. Sacco, R. Bientinesi, C. Gandi, L. Vaccarella, M. Racioppi, F. Pinto, A. Totaro, G. Palermo, P. Bassi

    • 9 September 2015
      • Vol. 68  (3) , 282-92

    Local relapse of prostate cancer after primary definitive treatment: the management.

    by Giuseppe Palermo, Nazario Foschi, Daniele D'Agostino, E Sacco, P Bassi, F Pinto

    Prostate cancer (PCa) is the most commonly diagnosed malignancy in men and the second leading cause of cancer-related death in industrialized countries. Even if the healing chances are very high after definitive treatment of localized disease, 20-30% of patients experience recurrence. A review of the literature on the management of local recurrent prostate cancer was conducted using the Medline and Embase electronic databases. Search terms included "biochemical relapse", "PSA recurrence", "prostate cancer", "prostate cancer recurrence", "prostate salvage therapy", "radiorecurrent prostate cancer", "Re-HIFU", "post HIFU", "post cryoablation", "postradiation", and "postprostatectomy salvage". The search was restricted to English-language articles. The websites of guidelines organizations (EAU, AUA, NICE) were consulted in order to identify evidence-based practice guidelines. The present role of salvage prostatectomy and radiation therapy was studied and today's outcomes and tomorrow perspectives of salvage focal therapies as cryoablation and HIFU have been analyzed. Although the treatment landscape for patients with biochemical recurrence prostate cancer remains challenging, new research is helping to identify patient populations suitable for specific therapies. Further evaluation in prospective clinical trials will hopefully confirm the role of therapeutic options in clinical practice and the impact on the long-term survival.


  • Immunohystochemical analysis of SOCS3 in prostatic adenocarcinoma biopsies.

    by F. Pierconti, T. Cenci, C. Pozzo, F. Pinto, A. Totaro, P. F. Bassi, L. M. Larocca

    E15132 Background: Chronic inflammation and the subsequent tissutal alterations may play a key role in prostate carcinogenesis. Molecular alterations of the suppressor of cytokine signaling (SOCS)3, can contribute to explain the pleiotropic role of interleukin (IL)-6 in this type of cancer. In a recent study, we demonstrated that methylation of SOCS3 may be involved in the pathogenesis of prostate cancer and could identify in a subset of tumor with an aggressive behavior. Methods: We analyzed the protein expression of SOCS3 by immunohistochemistry in 50 prostate cancer biopsies: 30 prostatic carcinoma with Gleason score 7, 10 with Gleason score 7. Slides were incubated with monoclonal antibody SOCS3 (1E4) (1.5 mg/ml; Abnova, Taiwan). The SOCS3 staining intensity were evaluated by two pathologist (FP and LML) in three different way: positive; negative; weak intensity staining with negative neoplastic glands. Colonic mucosa were used as positive control. Results: SOCS3 positive were found in all cases of adenocarcinoma Gleason score < 7 and in 10 cases with Gleason score 7, negative staining were found in all cases of adenocarcinoma Gleason score > 7 and in 8 cases with Gleason score 7. Weak SOCS3 staining with presence of negative neoplastic glands were found in 12 cases of adenocarcinoma Gleason score 7. The group of tumor SOCS3 negative were significantly more aggressive than group SOCS3 positive in terms of TNM stage,positivity of surgical margin. Cases with weak SOCS3 staining and negative neoplastic glands displayed more aggressive clinical behavior than cases SOCS3 positive (increase number of T3a and positive surgical margins), on the other hand unlike SOCS3 negative no stage T3b and lymphnode metastasis were found. Conclusions: Immunohystochemical analysis of SOCS3 protein unlike methylathion study identify three different groups of tumors: positive, negative and with weak SOCS3 staining with the presence of negative neoplastic glands. In this last group the reduction of expression protein and the presence of negative neoplastic glands could indicate an intermediate stage of tumor turning towards shutdown of SOCS3 and thus object of strict follow-up and suitable to demethylating agents therapy.

  • 572 LOWER URINARY TRACT SYMPTOMS AND URINARY COMPLICATIONS IN PATIENTS WITH MULTIPLE SCLEROSIS: EVALUATION IN A CONTEMPORARY COHORT FROM A REFERRAL CENTER

    by E. Sacco, A. Sebastianelli, A. Batocchi, A. Marti, A. Totaro, D. Tienforti, E. Cappa, D. D'Agostino, A. D'Onofrio, M. Vittori, et al.

    • 5 October 2010
      • Vol. 77  (2) , 92-9

    [Doping and urologic tumors].

    by F Pinto, E Sacco, A Volpe, M Gardi, A Totaro, A Calarco, M Racioppi, G Gulino, A D'Addessi, P F Bassi

    Several substances such as growth hormone (GH), erythropoietin (Epo), and anabolic steroids (AS) are improperly utilized to increase the performance of athletes. Evaluating the potential cancer risk associated with doping agents is difficult since these drugs are often used at very high doses and in combination with other licit or illicit drugs. The GH, via its mediator, the insulin-like growth factor 1 (IGF-1), is involved in the development and progression of cancer. Animal studies suggested that high levels of GH/IGF-1 increase progression of androgen-independent prostate cancer. Clinical data regarding prostate cancer are mostly based on epidemiological studies or indirect data such as IGF-1 high levels in patients with prostate cancer. Even if experimental studies showed a correlation between Epo and cancer, no clinical data are currently available on cancer development related to Epo as a doping agent. Androgens are involved in prostate carcinogenesis modulating genes that regulate cell proliferation, apoptosis and angiogenesis. Most information on AS is anecdotal (case reports on prostate, kidney and testicular cancers). Prospective epidemiologic studies failed to support the hypothesis that circulating androgens are positively associated with prostate cancer risk. Currently, clinical and epidemiological studies supporting association between doping and urological neoplasias are not available. Nowadays, exposure to doping agents starts more prematurely with a consequent longer exposition period; drugs are often used at very high doses and in combination with other licit or illicit drugs. Due to all these elements it is impossible to predict all the side effects, including cancer; more detailed studies are therefore necessary.


  • Correlation of epigenetic silencing of SOCS3 with a subset of prostate cancer with aggressive behavior.

    by F. Pierconti, M. Martini, T. Cenci, F. Pinto, P. Bassi, L. Larocca

    4646 Background: Chronic inflammation and the subsequent tissutal alterations may play a key role in prostate carcinogenesis. In this way, molecular alterations of the suppressor of cytokine signaling (SOCS) 3, one of the most important inhibitory molecule of the inflammatory signal transduction circuitries, could contribute to explain the pleiotropic role of interleukin (IL)-6 in this type of cancer. Methods: We analyzed the methylation status and mRNA expression of SOCS3 in 20 benign prostate hyperplasias (BPH) and in 51 prostate cancer specimens. After DNA modification with bisulphite, we analyzed the SOCS3 methylation status using Methylation-Specific PCR (MSP-PCR). Hypermethylation was confirmed by sequencing after subcloning. In addition, epigenetic silencing of this gene was also confirmed by real-time PCR. We statistically analyzed the correlation between our results and clinical data. Results: We found that the promoter of SOCS3 was methylated in 39.2% of prostate cancer. On the contrary, all BPH and normal controls had an unmethylated pattern. Real-time analysis showed that in methylated cases mRNA expression for SOCS3 was reduced by 3 and 4 folds as compared to BPH and unmethylated prostate cancer, respectively. Interestingly, SOCS3 mRNA was more expressed in unmethylated prostate cancer than in BPH. Moreover, methylation of SOCS3 promoter significantly associated with intermediate-high grade Gleason score (p=0.0007) and with an unfavorable clinical outcome (p=0.0019). In addition, we found a concordant result in the methylation status of SOCS3 both in biopsies and in prostate after surgical resection. Conclusions: Our data suggest that methylation of SOCS3 may be involved in the pathogenesis of prostate cancer and could identify in the bioptic specimen the subset of tumor with an aggressive behavior. In conclusion, SOC3 methylation could be a new prognostic marker and novel target for therapy. No significant financial relationships to disclose.

  • Regenerative medicine: applications and development in urology

    by F. Pinto, A. Calarco, A. Brescia, E. Sacco, A. D'Addessi, M. Racioppi, P.F. Bassi

  • Peyronie’s disease: state of the art and future perspectives

    by G. Gulino, F. Sasso, R. Falabella, M. Racioppi, E. Sacco, A. D'Onofrio, P.F. Bassi

  • Long-Term Results of Surgical Management of Pulmonary Metastases from Renal Cell Carcinoma

    by G. Marulli, F. Sartori, P. F. Bassi, F. Dal Moro, A. Gino Favaretto, F. Rea

    Background: Metastatic renal cell carcinoma (RCC) has a poor prognosis and conventional treatments such as chemoradiotherapy show little efficacy. Surgical resection of pulmonary metastases from RCC is a widely accepted treatment, even if selection criteria based on prognostic factors have still not been defined. The aim of this study was to determine the long-term survival, clinical outcome and prognostic factors after surgery. Methods: Between 1988 and 2004, 59 patients underwent resection of pulmonary metastases from RCC. Univariate and multivariate analysis of prognostic factors was carried out. Results: Complete resection was achieved in 54 (91.5 %) patients. No intra- or postoperative mortality occurred, 5 (8.5 %) patients experienced postoperative complications. Overall, the 1-, 3-, and 5-year survival rates were 86.5 %, 63 % and 53 %, respectively. Age at the time of pulmonary resection was found to be the only independent factor influencing prognosis. Conclusion: Pulmonary resection of metastases from RCC is a safe and effective treatment associated with a low morbidity and mortality and with high long-term survival. The lack of other effective therapies suggests use of the surgical approach whenever possible.


  • Pharmacokinetic Study of Intravesical Gemcitabine in Carcinoma in situ of the Bladder Refractory to Bacillus Calmette-Guérin Therapy

    by P. Bassi, V. De Marco, I.M. Tavolini, F. Longo, F. Pinto, M. Zucchetti, E. Crucitta, L. Marini, F. Dal Moro

    Introduction: Gemcitabine, a chemotherapeutic agent, has been shown to be active against transitional cell cancer of the bladder. The aim of the study was to determine the pharmacokinetic profile of gemcitabine, administered intravesically in patients with carcinoma in situ(CIS). Material and Methods: Nine patients with CIS refractory to intravesical bacillus Calmette-Guérin (BCG) therapy were enrolled. Gemcitabine was given in 50 ml 0.9% NaCl by catheterization and held in the bladder for 1 h, once weekly for 6 consecutive weeks. The pharmacokinetics for gemcitabine metabolites were performed in plasma and serum. Dose levels were: 1,000, 1,250, and 1,500 mg. Clinical evaluation was repeated 4 weeks after therapy and thereafter every 6 months. Results: Grade-1 neutropenia was observed only in 1 patient. Grade-1 urinary frequency and hematuria were observed in 1 and 3 patients, respectively. No grade 2–4 toxicity or clinically relevant myelosuppression were observed. Gemcitabine was detectable in serum, but with an irrelevant pharmacological effect, in only 1 patient treated with 1,500 mg of gemcitabine. With regard to activity, after 6 instillations of this drug, 4 complete responses were observed. Conclusion: Intravesical gemcitabine is well tolerated and safe. No systemic absorption with a clinical or pharmacological effect was detected and only slightly irritative bladder symptoms were observed. These results warrant further investigation in phase-II trials.